Publication | Closed Access

A Randomized, Open-Label Phase II Trial of Volasertib as Monotherapy and in Combination With Standard-Dose Pemetrexed Compared With Pemetrexed Monotherapy in Second-Line Treatment for Non–Small-Cell Lung Cancer

Second-line TreatmentMedicinePemetrexed MonotherapyMetronomic TherapyPharmacologyClinical TrialsBronchial NeoplasmPharmacotherapyCancer TreatmentOncologyStandard-dose Pemetrexed ComparedLung Cancer